Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER

(PFE)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
03/18/2019 03/19/2019 03/20/2019 03/21/2019 03/22/2019 Date
41.81(c) 42.3(c) 42.17(c) 42.35(c) 41.85(c) Last
18 021 218 25 050 546 22 295 088 23 019 526 18 501 838 Volume
+0.07% +1.17% -0.31% +0.43% -1.18% Change
More quotes
Financials (USD)
Sales 2019 53 331 M
EBIT 2019 19 994 M
Net income 2019 12 143 M
Debt 2019 32 038 M
Yield 2019 3,43%
Sales 2020 54 152 M
EBIT 2020 20 570 M
Net income 2020 12 862 M
Debt 2020 30 114 M
Yield 2020 3,59%
P/E ratio 2019 19,27
P/E ratio 2020 16,75
EV / Sales2019 4,96x
EV / Sales2020 4,85x
Capitalization 232 B
More Financials
Company
Pfizer the world's leading pharmaceutical group. Net sales break down by family of products as follows: - vaccines, oncology products and consumer medicines (59.8%); - generic medicines (40.2%): for treating cardio-vascular diseases, nervous system disorders, infectious and respiratory diseases,... 
Sector
Pharmaceuticals
Calendar
04/13Presentation
More about the company
Surperformance© ratings of Pfizer
Trading Rating : Investor Rating :
More Ratings
Latest news on PFIZER
03/23PFIZER : buys stake in French gene therapy company Vivet
AQ
03/21PFIZER : Description Notice of exempt solicitation. Definitive material.
PU
03/21ERNESTO BERTARELLI : French healthcare group Stallergenes to be bought out by Be..
RE
03/21PFIZER : Adds to Streak of Deals in Gene Therapies
DJ
03/20Merck KGaA, Pfizer End Phase III Trial in Previously Untreated Advanced Ovari..
DJ
03/20PFIZER : Adds to Big Pharma's Gene-Therapy Deal Streak
DJ
03/20PFIZER : Takes 15% Stake in Gene-Therapy Biotech Vivet Therapeutics
DJ
03/20PFIZER : Secures Exclusive Option to Acquire Gene Therapy Company Vivet Therapeu..
BU
03/19MERCK KGAA : Darmstadt, Germany, and Pfizer Announce Discontinuation of Phase II..
PR
03/19PFIZER : Invites Public to View and Listen to Webcast of April 30 Conference Cal..
BU
More news
Analyst Recommendations on PFIZER
More recommendations
Sector news : Pharmaceuticals - NEC
03/22FDA Rejects Oral Treatment for Type 1 Diabetes - Update
DJ
03/22ALLERGAN : promises independent board chair in next leadership change
RE
03/22FDA Rejects Oral Treatment for Type 1 Diabetes
DJ
03/22UPS to Test In-Home Vaccine Service in U.S. -Reuters
DJ
03/22JOHNSON & JOHNSON : J&J Unit Seeks Europe OK of Darzalex Combination in Multiple..
DJ
More sector news : Pharmaceuticals - NEC
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Average target price 44,1 $
Spread / Average Target 5,5%
EPS Revisions
Managers
NameTitle
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-4.12%232 343
JOHNSON & JOHNSON6.09%364 560
NOVARTIS10.71%239 248
ROCHE HOLDING LTD.10.68%233 745
MERCK AND COMPANY7.70%212 409
ELI LILLY AND COMPANY10.87%132 844